Gino Santini and Daniel Welch Elected to Board of Directors of Intercept Pharmaceuticals
December 11, 2015 07:05 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
Intercept Pharmaceuticals Announces Initiation of Prospective Trial to Explore Effect of Combined OCA and Statin Therapy on Lipid Metabolism in NASH Patients
December 07, 2015 07:05 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Dec. 7, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
Intercept to Present at the Oppenheimer Healthcare Conference
December 02, 2015 16:05 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Dec. 2, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
Intercept Pharmaceuticals Initiates Phase 1 Study of INT-767, a Dual FXR and TGR5 Agonist
November 30, 2015 16:05 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
Intercept Presents New PBC Data at AASLD 2015
November 14, 2015 14:07 ET
|
Intercept Pharmaceuticals, Inc.
Research Demonstrates Scope of Unmet Need in PBC
New Analysis of Phase 3 POISE Study Uses Risk Algorithm to Examine Potential of OCA to Lower Patients' Long-Term Risk of Liver Transplant and...
Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015
November 14, 2015 10:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 14, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
Intercept Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Business Update
November 09, 2015 07:05 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting
November 03, 2015 07:05 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...
Intercept to Report Third Quarter 2015 Financial Results on November 9th
November 02, 2015 16:05 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
Intercept Pharmaceuticals Announces Results of Phase 2 Trial of OCA in NASH Patients in Japan
October 28, 2015 07:30 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...